Scott T. Tagawa   Professor of Medicine

Phone

Genitourinary Cancer: Clinical Trials

Dr. Tagawa leads clinical trials in prostate, renal (kidney), and urothelial (bladder) cancers. The genitourinary section of the solid tumor program includes local, regional, national, and international trials. Weill-Cornell is a main member institution of Cancer and Leukemia Group B (CALGB) and Dr. Tagawa actively participates in the genitourinary section of this national cancer research group. In addition, clinical trials are available through a contract with the National Cancer Institute (NCI) as part of the New York Cancer Consortium.Dr. Tagawa has a specific interest in monoclonal antibody directed therapy, in particular using antibodies against prostate specific membrane antigen (PSMA) and holds grants in this area. He leads clinical trials using radioimmunotherapy (small radioactive particles linked to the antibody) to fight metastatic prostate cancer, to prevent or delay metastatic disease in men with a rising PSA, and targeting tumor vasculature in advanced solid tumors.

Publications

Sort by

selected publications

Research

Sort by

Funding awarded

Background

Contact

full name

  • Scott T. Tagawa

primary email

  • stt2007@med.cornell.edu

External Relationships

externalRelationships

  • Relationships and collaborations with for-profit and not-for-profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

    Consultant refers to an individual who provides expert advice to a business or entity (e.g., consulting on medical devices or pharmaceuticals)Consultant:
    AbbVie Inc.; Abdera Therapeutics INC; AIkido Pharma Inc.; Ambrx, Inc.; Amgen, Inc.; Astellas Pharmaceuticals US, Inc.; Atlab Pharma SAS; Bayer Healthcare Pharmaceuticals; Blue Earth Diagnostics, Inc.; Clarity Pharmaceutical; Clovis Oncology, Inc.; Convergent Therapeutics, Inc; Daiichi Sankyo, Inc.; Dendreon Corporation; Eisai, Inc.; Endocyte, Inc.; Genentech, Inc.; General Electric Company; Gilead Sciences, Inc.; Immunomedics, Inc.; Janssen Biotech Inc.; Karyopharm Therapeutics, Inc.; Lantheus Medical Imaging, Inc.; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; QED Therapeutics; Regeneron Pharmaceuticals, Inc.; Sanofi-Aventis - DEACTIVATED DUPLICATE; Seattle Genetics, Inc.; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.
    Other Interests refers to miscellaneous financial interests not covered in other categories (e.g., stipends, anything of monetary value)Other Interest:
    Merck; POINT Biopharma Inc.
    Ownership refers to any financial stake an individual owns in any company (e.g., stock options, equity interest)Ownership:
    AIkido Pharma Inc.; Convergent Therapeutics, Inc
    Professional Services refers to a service requiring specialized knowledge and skill usually requiring a license, certification, or registration (e.g., expert witness, commissioned writing)Professional Services:
    Boston Scientific Corporation; Cancer Research UK
    Proprietary Interest refers to ownership of intellectual property rights (e.g., trademarks, patents, royalty income)Proprietary Interest:
    Gilead Sciences, Inc.
    Speaker/Lecturer refers to an individual who conducts professional lectures, speeches, or presentations (e.g., educational speaking engagement, company sponsored speaker)Speaker/Lecturer:
    Amgen, Inc.; Dendreon Corporation